REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
Key Highlights
- ➤REGENXBIO investor event scheduled October 20, 2026, focused on sura-vec in wet AMD
- ➤Topline pivotal wet AMD data anticipated in fourth quarter of 2026
- ➤Event will cover ATMOSPHERE and ASCENT pivotal trials and commercial readiness
- ➤Leading retina specialists will provide perspectives on sura-vec and wet AMD treatment landscape
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 PR Newswire
* Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026 ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will host an investor event at 1:00 p.m. ET on Tuesday, October 20, 2026 to review the surabgene lomparvovec (sura-vec, ABBV-RGX-314) clinical program in wet age-related macular degeneration (wet AMD) ahead of the topline pivotal data anticipated in the fourth quarter of 2026. The event will be held in-person in New York, NY and available via webcast.
Get started
Create a free account to read the full story.